14 July 2023 in Biomacromolecules
V(III) instead of commonly used Fe(III) provided a rich tris-catechol-metal coordination at pH 7.4, which is important for slow drug release at physiological pH. Bovine serum albumin (BSA) functionalized with catechol-containing dopamine (D) and cross-linked using tris-catechol-V(III) coordination yielded pH-responsive compact D-BSA NPs (253 nm). However, conversion to bis- and/or mono-catechol-V(III) complexes in an acidic medium resulted in degradation of NPs and rapid release of doxorubicin (DOX). It was shown that D-BSA NPs entered cancerous MCF-7 cells (66%) more efficiently than non-cancerous HEK293T (33%) in 3 h. Also, DOX-loaded NPs reduced cell viability of MCF-7 by 75% and induced apoptosis in a majority of cells after 24 h. Biodegradability and lack of hemolytic activity were shown in vitro, whereas a lack of toxicity was shown in histological sections of zebrafish. Furthermore, 30% of circulating tumor cells in vasculature in 24 h were killed by DOX-loaded NPs shown with the zebrafish CTC xenograft model.
19 January 2024 in Talanta
17 February 2026 in The FEBS Journal
GKGkamze Impraimoglou Kafaz
Gkamze Impraimoglou Kafaz
+4
25 January 2024 in bioRxiv
Macular corneal dystrophy (MCD) is a rare congenital disease caused by mutations in the carbohydrate sulfotransferase 6 ( chst6 ) gene. Patients suffer from opaque aggregates in the cornea leading to bilateral progressive vision loss by 4 th decade of life. Corneal transplantation is the only available treatment, which is invasive, not available to every patient and recurrence of the symptoms is common. Keratocytes in the cornea express the chst6 gene, which encodes a golgi enzyme that is essential for sulfation of the keratan sulfate proteoglycans (KSPG). The loss of KS sulfation leads to defects in collagen fibril organization and aggregate formation in the corneal extracellular matrix. Lack of preclinical disease models is a major limitation for the development of accessible treatment strategies. Attempts to develop mouse MCD models have failed due to lack of chst6 gene in mice and difference in proteoglycan composition of the mouse cornea. The zebrafish chst6 gene has not been studied previously. Zebrafish cornea structure is highly similar to humans, containing high levels of keratan sulfate proteoglycans in the stroma. Here, loss of function chst6 mutant zebrafish were generated with CRISPR/Cas9 mediated gene editing. Several chst6 alleles were obtained, and loss of KSPG sulfation in the eye stroma was shown. Mutant zebrafish developed age-dependent, alcian blue positive, opaque accumulates in the cornea. Degeneration of corneal structure and changes in epithelial thickness were observed. The zebrafish MCD model developed here is the first in vivo model of the disease and opens up possibilities to develop and screen treatment strategies. Significance Statement: First in vivo model of macular corneal dystrophy (MCD) is reported in this study. Zebrafish model developed here paves the way for modeling of other corneal dystrophies in this aquatic vertebrate which is easy to apply therapeutics and image in vivo . The clinical symptoms of MCD are well reproduced in the zebrafish MCD model. Moreover, the authors showed that chst6 gene function is not restricted to cornea, and a fraction of mutant larvae have morphological defects. The mutants developed here provide a genetic model for understanding the highly complex roles of keratan sulfate proteoglycans.